Mabwell (Shanghai) Bioscience Co., Ltd.

Related records

Trials (53)

• 6MW3511 in Patients With Advanced Solid Tumor
• 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
• 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
• 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
• 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
• 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
• A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection
• A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection
• A Clinical Study of 6MW3211 in Patients With Renal Cancer
• A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
• A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
• A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
• A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
• A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
• A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
• A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
• A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
• A Clinical Study to Evaluate MW33 Injection
• A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
• A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia